Search

Your search keyword '"Kutum R"' showing total 2 results
Start Over Author "Kutum R" Topic covid-19
2 results on '"Kutum R"'

1. High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge.

Author

Ujjainiya R, Tyagi A, Sardana V, Naushin S, Bhatheja N, Kumar K, Barman J, Prakash S, Kutum R, Bhaskar AK, Singh P, Chaudhary K, Loomba M, Khanna Y, Walecha C, Ahmed R, Yadav A, Bajaj A, Malik G, Qureshi S, Waghdhare S, Siddiqui S, Trehan KK, Mani M, Dang R, Das P, Dougall P, Mahajan M, Sonar S, Jakhar K, Kumar R, Tiwari M, Mani S, Bhattacharyya S, Budhiraja S, Agrawal A, Dash D, Jha S, and Sengupta S

Subjects
Health Personnel, Humans, Immunization, SARS-CoV-2, Vaccination, Asymptomatic Infections, COVID-19 epidemiology, COVID-19 prevention & control
Abstract

Immunization is expected to confer protection against infection and severe disease for vaccines while reducing risks to unimmunized populations by inhibiting transmission. Here, based on serial serological studies of an observational cohort of healthcare workers, we show that during a Severe Acute Respiratory Syndrome -Coronavirus 2 Delta-variant outbreak in Delhi, 25.3% (95% Confidence Interval 16.9-35.2) of previously uninfected, ChAdOx1-nCoV19 double vaccinated, healthcare workers were infected within less than two months, based on serology. Induction of anti-spike response was similar between groups with breakthrough infection (541 U/ml, Inter Quartile Range 374) and without (342 U/ml, Inter Quartile Range 497), as was the induction of neutralization activity to wildtype. This was not vaccine failure since vaccine effectiveness estimate based on infection rates in an unvaccinated cohort were about 70% and most infections were asymptomatic. We find that while ChAdOx1-nCoV19 vaccination remains effective in preventing severe infections, it is unlikely to be completely able to block transmission and provide herd immunity., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

2. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.

Author

Naushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, Pradhan S, Prakash S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Chandak GR, Lahiri A, Kar S, Mulay SR, Mugale MN, Srivastava M, Khan S, Srivastava A, Tomar B, Veerapandian M, Venkatachalam G, Vijayakumar SR, Agarwal A, Gupta D, Halami PM, Peddha MS, Sundaram GM, Veeranna RP, Pal A, Agarwal VK, Maurya AK, Singh RK, Raman AK, Anandasadagopan SK, Karuppanan P, Venkatesan S, Sardana HK, Kothari A, Jain R, Thakur A, Parihar DS, Saifi A, Kaur J, Kumar V, Mishra A, Gogeri I, Rayasam G, Singh P, Chakraborty R, Chaturvedi G, Karunakar P, Yadav R, Singhmar S, Singh D, Sarkar S, Bhattacharya P, Acharya S, Singh V, Verma S, Soni D, Seth S, Vashisht S, Thakran S, Fatima F, Singh AP, Sharma A, Sharma B, Subramanian M, Padwad YS, Hallan V, Patial V, Singh D, Tripude NV, Chakrabarti P, Maity SK, Ganguly D, Sarkar J, Ramakrishna S, Kumar BN, Kumar KA, Gandhi SG, Jamwal PS, Chouhan R, Jamwal VL, Kapoor N, Ghosh D, Thakkar G, Subudhi U, Sen P, Chaudhury SR, Kumar R, Gupta P, Tuli A, Sharma D, Ringe RP, D A, Kulkarni M, Shanmugam D, Dharne MS, Dastager SG, Joshi R, Patil AP, Mahajan SN, Khan AH, Wagh V, Yadav RK, Khilari A, Bhadange M, Chaurasiya AH, Kulsange SE, Khairnar K, Paranjape S, Kalita J, Sastry NG, Phukan T, Manna P, Romi W, Bharali P, Ozah D, Sahu RK, Babu EV, Sukumaran R, Nair AR, Valappil PK, Puthiyamadam A, Velayudhanpillai A, Chodankar K, Damare S, Madhavi Y, Aggarwal VV, Dahiya S, Agrawal A, Dash D, and Sengupta S

Subjects
Biomarkers blood, COVID-19 diagnosis, COVID-19 immunology, COVID-19 virology, Female, Host-Pathogen Interactions, Humans, Immunity, Humoral, India epidemiology, Longitudinal Studies, Male, Predictive Value of Tests, Risk Assessment, Risk Factors, Seroepidemiologic Studies, Time Factors, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 epidemiology, COVID-19 Serological Testing, SARS-CoV-2 immunology
Abstract

To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001)., Competing Interests: SN, VS, RU, NB, RK, AB, SP, SP, RK, BR, KT, MA, GC, AL, SK, SM, MM, MS, SK, AS, BT, MV, GV, SV, AA, DG, PH, MP, GS, RV, AP, VA, AM, RS, AR, SA, PK, SV, HS, AK, RJ, AT, DP, AS, JK, VK, AM, IG, GR, PS, RC, GC, PK, RY, SS, DS, SS, PB, SA, VS, SV, DS, SS, SV, ST, FF, AS, AS, BS, MS, YP, VH, VP, DS, NT, PC, SM, DG, JS, SR, BK, KK, SG, PJ, RC, VJ, NK, DG, GT, US, PS, SC, RK, PG, AT, DS, RR, AD, MK, DS, MD, SD, RJ, AP, SM, AK, VW, RY, AK, MB, AC, SK, KK, SP, JK, NS, TP, PM, WR, PB, DO, RS, EB, RS, AN, PV, AP, AV, KC, SD, YM, VA, SD, AA, DD, SS No competing interests declared, (© 2021, Naushin et al.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results